



Docetaxel 75 / Cisplatin 75, Non-Small Cell Lung Carcinoma

Protocol-ID: 144 V1.1 (Basic), DOCE75/CISP75, NSCLC

Indication(s)

- Lung Carcinoma, Non-Small Cell; ICD-10 C34.-

Cycles

Cycle length 21 days, recommended cycles: 6

References

- Schiller JH, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 Jan 10;346(2):92-8. doi: 10.1056/NEJMoa011954. PMID: 11784875. [\[PMID\]](#)
- Millward MJ, Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1997 Feb;15(2):750-8. doi: 10.1200/JCO.1997.15.2.750. PMID: 9053501. [\[PMID\]](#)
- Fossella F, Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group J Clin Oncol 2003 Aug 15;21(16):3016-24. doi: 10.1200/JCO.2003.12.046. PMID: 12837811. [\[PMID\]](#)
- Novello S, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016 Sep;27(suppl 5):v1-v27. doi: 10.1093/annonc/mdw326. PMID: 27664245. [\[PMID\]](#)

Recommendations

- 09/2021: [European Society for Medical Oncology](#)
- 02/2023: [National Comprehensive Cancer Network](#)

Important notice

The copyrighted protocols are treatment recommendations. The information contained in this compilation on cytostatic drugs, concomitant medication and other therapeutic procedures, as well as dosage and application information, is continuously reviewed with all due care by the authors and editors involved. Nevertheless, the publishers and authors do not assume any liability for the correctness - also with regard to possible printing errors.

The protocols may not be changed in terms of content.

Diagnosis, indication for therapy and treatment of malignant diseases must be carried out in each individual case by the hematologist and oncologist on his or her own responsibility. The treating physician is obligated to this personal responsibility to weigh in each case before a diagnostic or therapeutic measure, indication, contraindications, dosage and application under consideration of the specialized information or other documents of the manufacturers. This applies in particular to rarely used preparations or preparations that are new to the market.



The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 22.02.2023